2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-13463B
    Avatrombopag hydrochloride 570403-17-7
    Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A.
    Avatrombopag hydrochloride
  • HY-135517
    RXP470.1 891198-31-5 99.60%
    RXP470.1 (RXP-470) is a potent, selective MMP-12 inhibitor with a Ki of 0.2 nM against human MMP-12. RXP470.1 is 2 to 4 orders of magnitude less potent against other MMPs. RXP470.1 significantly reduces atherosclerotic plaque cross-sectional area in mouse. RXP470.1 results in less complex plaques with increased smooth muscle cell:macrophage ratio, less macrophage apoptosis, increased cap thickness, smaller necrotic cores, and decreased incidence of calcification.
    RXP470.1
  • HY-136304
    NHS-PEG1-SS-PEG1-NHS 1688598-83-5 98.0%
    NHS-PEG1-SS-PEG1-NHS is a reversible linker for biomacromolecule link with active small molecule. NHS-PEG1-SS-PEG1-NHS can be used in proteins liposomes or nanoparticles.
    NHS-PEG1-SS-PEG1-NHS
  • HY-136909
    SR33805 121345-64-0 99.78%
    SR33805 is a potent Ca2+ channel antagonist, with EC50s of 4.1 nM and 33 nM in depolarized and polarized conditions, respectively. SR33805 blocks L-type but not T-type Ca2+ channels. SR33805 can be used for the research of acute or chronic failing hearts.
    SR33805
  • HY-138822
    2,3-Diphospho-D-glyceric acid pentasodium salt 102783-53-9
    2,3-Diphospho-D-glyceric acid (2,3-DPG) pentasodium salt is a hemoglobin binder and vascular calcification inhibitor that reduces the oxygen affinity of hemoglobin. 2,3-Diphospho-D-glyceric acid pentasodium salt also specifically delays the transformation of colloidal calciprotein particles into crystalline forms, thereby effectively inhibiting vascular smooth muscle cell calcification without affecting the normal formation of osteoid nodules in osteoblast-like cells. 2,3-Diphospho-D-glyceric acid pentasodium salt shows no cytotoxicity to tested cell lines and only weakly interferes with β-hematin formation mediated by glyceryl monopalmitate. 2,3-Diphospho-D-glyceric acid pentasodium salt can be used to study the pathological mechanisms of vascular calcification and malaria-related conditions.
    2,3-Diphospho-D-glyceric acid pentasodium salt
  • HY-141645
    IMM-H007 1221412-23-2
    IMM-H007 (WS070117) is an orally active and potent AMPK (AMP-activated protein kinase) activator and TGFβ1 (transforming growth factor β1) antagonist. IMM-H007 has protective effects in cardiovascular diseases via activation of AMPK. IMM-H007 negatively regulates endothelium inflammation through inactivating NF-κB and JNK/AP1 signaling. IMM-H007 inhibits ABCA1 degradation. IMM-H007 resolves hepatic steatosis in HFD-fed hamsters by the regulation of lipid metabolism. IMM-H007 can be used for the research of nonalcoholic fatty liver disease (NAFLD) and inflammatory atherosclerosis.
    IMM-H007
  • HY-144549
    LXR agonist 1 1779524-90-1 99.95%
    LXR (Liver X receptor) agonist 1 is potent LXR agonist with AC50s of 1.5 nM and 12 nM for LXR-α and LXR-β, respectively. LXR agonist 1 has the potential for the research of atherosclerosis.
    LXR agonist 1
  • HY-145154
    Digoxigenin monodigitoxoside 5352-63-6 98.0%
    Digoxigenin monodigitoxoside, a metabolite of Digoxin (HY-B1049), belongs to the class of cardenolides. Digoxigenin monodigitoxoside exerts its function by inhibiting Na,K-ATPase. Digoxigenin monodigitoxoside is used for the research of cardiovascular diseases such as congestive heart failure and cardiac arrhythmias.
    Digoxigenin monodigitoxoside
  • HY-148055
    Wnt/β-catenin agonist 3 912790-59-1 99.87%
    Wnt/β-catenin agonist 3 (compound 98) is a Wnt/β-catenin signalling pathway agonist. Wnt/β-catenin agonist 3 can be used for the research of osteoporosis.
    Wnt/β-catenin agonist 3
  • HY-148758
    PCSK9-IN-13 2244129-23-3 98.00%
    PCSK9-IN-13(compound 3f) is a potent PCSK9 inhibitor, which can antagonize low-density lipoprotein (LDL) receptor binding by binding to PCSK9, with an IC50 of 537 nM.
    PCSK9-IN-13
  • HY-15895S
    Aprocitentan-d4 2748196-51-0 98.76%
    Aprocitentan-d4 is a deuterium labeled Aprocitentan. Aprocitentan is a major and pharmacologically active metabolite of Macitentan. Aprocitentan is an orally active dual ETA/ETB antagonist with IC50s of 3.4 nM and 987 nM, and pA2 valus of 6.7 and 5.5, respectively. Aprocitentan is an antihypertensive agent.
    Aprocitentan-d4
  • HY-161104
    Kv2.1-IN-1 2252448-93-2 98.64%
    Kv2.1-IN-1 is an orally active and blood-brain barrier penetrant Kv2.1 inhibitor with an IC50 of 0.07 μM. Kv2.1-IN-1 exhibits a selectivity >130 fold over other K+, Na+, and Ca2+ ion channels. Kv2.1-IN-1 decreases the apoptosis of HEK293 cells induced by H2O2. Kv2.1-IN-1 produces significant neuroprotection efficacy in middle cerebral artery occlusion (MCAO) rat. Kv2.1-IN-1 can be used for the study of ischemic stroke.
    Kv2.1-IN-1
  • HY-162235
    CVN766 1803557-42-7 98.31%
    CVN766 is an orally active inhibitor of orexin 1 receptor antagonist with blood-brain permeability with the IC50 values of 8 nM and >10 μM for OX1R and OX2R, respectively. CVN766 can be used for study schizophrenia.
    CVN766
  • HY-164254
    Cardiomyocyte proliferation promoting agent-1 2351906-71-1 99.87%
    Cardiomyocyte proliferation promoting agent-1 ((E/Z)-GA-002), which is an E/Z mixture, is a cardiomyocyte proliferation promoter. GA-002 (single E configuration) is a kinase inhibitor for LATS1 and LATS2, with its IC50 values being 3.93 nM and 3.87 nM respectively. GA-002 can induce the expression of genes regulated by the Hippo pathway, inhibit the phosphorylation of YAP/TAZ, and induce the nuclear translocation of YAP.
    Cardiomyocyte proliferation promoting agent-1
  • HY-17502R
    Simvastatin (Standard) 79902-63-9 98.97%
    Simvastatin (Standard) is the analytical standard of Simvastatin. This product is intended for research and analytical applications. Simvastatin (MK 733) is a competitive inhibitor of HMG-CoA reductase with a Ki of 0.2 nM.
    Simvastatin (Standard)
  • HY-176716
    ALDH2 activator 1 2988020-77-3 98.88%
    ALDH2 activator 1 (Compound Z17) is an allosteric aldehyde dehydrogenase 2 (ALDH2) agonist. ALDH2 activator 1 enhances cardiac function and reduces myocardial necrosis in a mouse model of myocardial ischemia-reperfusion. ALDH2 activator 1 is promising for research of cardiovascular diseases such as myocardial infarction (MI).
    ALDH2 activator 1
  • HY-A0064R
    Verapamil hydrochloride (Standard) 152-11-4 99.81%
    Verapamil (hydrochloride) (Standard) is the analytical standard of Verapamil (hydrochloride). This product is intended for research and analytical applications. Verapamil hydrochloride ((±)-Verapamil hydrochloride) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil hydrochloride also inhibits CYP3A4. Verapamil hydrochloride has the potential for high blood pressure, heart arrhythmias and angina research.
    Verapamil hydrochloride (Standard)
  • HY-A0144A
    Etilefrine hydrochloride 943-17-9 99.90%
    Etilefrine hydrochloride is a sympathetic nerve agonist and AMPK activator that selectively targets α1/β1 adrenergic receptors. Etilefrine hydrochloride stimulates α1 adrenergic receptors, leading to contraction of vascular smooth muscle and increased peripheral resistance. Etilefrine hydrochloride also stimulates β1 receptors to enhance myocardial contractility and increase heart rate, thereby increasing blood pressure and improving cardiac output. Etilefrine hydrochloride also bidirectionally regulates the AMPK/Akt pathway and modulates the phosphorylation levels. Etilefrine hydrochloride can be used in cardiovascular research, such as postural hypotension, chylothorax, and improving low cardiac output.
    Etilefrine hydrochloride
  • HY-B0252R
    Hydrochlorothiazide (Standard) 58-93-5 99.55%
    Hydrochlorothiazide (Standard) is the analytical standard of Hydrochlorothiazide. This product is intended for research and analytical applications. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect.
    Hydrochlorothiazide (Standard)
  • HY-B0428A
    Ozagrel sodium 189224-26-8 99.82%
    Ozagrel sodium (OKY-046 sodium) is a high selective and orally active thromboxane A2 (TXA2) synthase inhibitor with an IC50 of 11 nM. Ozagrel sodium exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA2 and increasing the production of prostacyclin (PGI2). Ozagrel sodium can be used for the study of ischemic stroke, asthma and thromboembolic diseases.
    Ozagrel sodium
Cat. No. Product Name / Synonyms Application Reactivity